Bristol-Myers Squibb (BMY) Tops Q3 EPS by 4c; Boosts FY15 EPS Outlook

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/10/2026

1. SPCX
2. HUM
3. ALHC
4. T
5. PEP
6. CVS
7. UNH
8. SBUX
9. AXP
10. ZETA

Go back to Bristol-Myers Squibb (BMY) Tops Q3 EPS by 4c; Boosts FY15 EPS Outlook

Leerink Partners Remains Bullish After Opdivo and HCV Help Drive 3Q Beat for Bristol-Myers Squibb (BMY)

October 28, 2015 8:20 AM EDT

Leerink Partners reiterated an Outperform rating and $77.00 Price Target on Bristol-Myers Squibb Co. (NYSE: BMY) following 3Q earnings results. Non-GAAP EPS of $0.39 beat the Street estimates of $0.35. Global revenue was $4.1B, above consensus $3.9B expectations.

Analyst Seamus Fernandez commented, "BMY reported strong 3Q:15... More